BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $18.27, but opened at $19.44. BioAge Labs shares last traded at $18.6450, with a volume of 201,341 shares traded.

Analyst Ratings Changes

BIOA has been the topic of several research analyst reports. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Monday. Citigroup raised their price target on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Finally, Piper Sandler started coverage on BioAge Labs in a report on Tuesday. They set an “overweight” rating on the stock. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, BioAge Labs has an average rating of “Hold” and a consensus price target of $15.00.

BioAge Labs Stock Performance

The stock has a 50-day simple moving average of $13.62 and a 200 day simple moving average of $8.33. The stock has a market capitalization of $680.53 million, a P/E ratio of -12.47 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.

Insider Transactions at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total value of $216,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the sale, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at $17,702,315.88. This represents a 19.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 347,004 shares of company stock worth $5,673,859 in the last quarter. 20.82% of the stock is owned by company insiders.

Institutional Investors Weigh In On BioAge Labs

Several hedge funds have recently bought and sold shares of BIOA. Vanguard Group Inc. grew its holdings in shares of BioAge Labs by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after buying an additional 93,694 shares during the period. Geode Capital Management LLC grew its stake in BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after acquiring an additional 171,426 shares during the period. Millennium Management LLC increased its holdings in shares of BioAge Labs by 749.8% in the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after acquiring an additional 270,479 shares in the last quarter. Marshall Wace LLP raised its position in shares of BioAge Labs by 324.7% during the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after purchasing an additional 173,388 shares during the period. Finally, Stonepine Capital Management LLC grew its position in shares of BioAge Labs by 202.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.